SIGMADA 100 TAB is a psychotropic medication developed with Quetiapine Fumarate 100 mg, a second-generation antipsychotic belonging to the dibenzothiazepine class. It is widely used in psychiatric care for its effectiveness in controlling symptoms of schizophrenia, managing mood episodes in bipolar disorder, and serving as an adjunct in major depressive disorders when conventional antidepressants are insufficient.

This formulation works primarily by modulating neurotransmitter activity in the brain, particularly by antagonizing dopamine D2 and serotonin 5-HT2A receptors. The balanced receptor activity allows SIGMADA 100 TAB to reduce hallucinations, delusions, mood swings, and manic or depressive episodes. Its relatively lower risk of extrapyramidal side effects and its sedative properties also make it a suitable option for long-term psychiatric therapy.

SIGMADA 100 TAB is manufactured by Bluepill Express in WHO-GMP-certified units that comply with stringent international regulatory norms, including ISO and local FDA requirements. The tablets are developed through a precision-controlled granulation process to ensure uniformity, optimal disintegration, and efficient release of the active ingredient for sustained therapeutic outcomes.

The formulation is particularly effective in the maintenance therapy of schizophrenia, helping to stabilize cognitive functions and reduce relapse risks. In bipolar disorder, it assists in the management of acute manic or depressive episodes and supports mood stabilization over time. It is also used as part of combination therapy for treatment-resistant depression, making it versatile across multiple psychiatric protocols.

Each tablet of SIGMADA 100 is packaged in high-barrier aluminum-aluminum or aluminum-PVC blister packs to protect against moisture, contamination, and degradation, ensuring extended shelf life and product integrity during transit and storage. The product meets pharmacopeial specifications for assay, dissolution, and microbial limits.

Clinicians prefer SIGMADA 100 TAB for titration in moderate to severe cases, particularly when transitioning patients from lower doses or when increasing therapeutic coverage is needed. It provides an essential mid-range strength that bridges lower and higher dose regimens, giving flexibility in patient-specific treatment plans.

Bluepill Express offers SIGMADA 100 TAB as part of its export-ready psychiatric product portfolio with comprehensive support for third-party manufacturing, including private labeling, regulatory documentation (CTD/ACTD), branding customization, and international shipping logistics. The product is approved for distribution in markets across Asia, Africa, Latin America, and the Middle East.